Literature DB >> 20172008

Alteration in chromogranin A, obestatin and total ghrelin levels of saliva and serum in epilepsy cases.

Ersel Dag1, Suleyman Aydin, Yusuf Ozkan, Fazilet Erman, Adile Ferda Dagli, Mehtap Gurger.   

Abstract

This study was designed to measure the levels of chromogranin A (CgA), ghrelin and obestatin in serum and saliva (including CgA expression in healthy tissue) in epileptic patients to determine any significant differences between these patients and healthy controls. Samples were obtained from a total of 91 subjects: 10 newly-diagnosed primary generalized epilepsy (PGE) patients who had started treatment with valproic acid and phenytoin for seizure control; 18 PGE patients who were previously and currently receiving treatment with valproic acid and phenytoin for seizure control; 37 patients with partial epilepsy (PE) (simple, n=17 or complex, n=20) who had been and were still being treated with carbazebime for seizures; and 26 healthy controls. CgA immunoreactivity in healthy salivary gland was analyzed by immunohistochemistry and ELISA. The levels of CgA, total ghrelin and obestatin in serum and saliva were measured by ELISA. The results revealed that normal salivary gland produces its own CgA. Before treatment, CgA levels in saliva and serum were significantly greater in patients newly-diagnosed with PGE than controls. Ghrelin and CgA concentrations were also greater in PGE patients previously or currently treated with drugs, and in patients with simple or complex partial epilepsy (PE) previously or currently treated with drugs, than in healthy normal controls. In conclusion, salivary concentrations of CgA, ghrelin and obestatin were similar to their serum levels, so saliva might be a desirable alternative to serum for measuring these hormones because it is easy and painless to collect. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172008     DOI: 10.1016/j.peptides.2010.02.009

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  11 in total

1.  An IgY-based immunoassay to evaluate the biomarker potential of the Tannerella forsythia virulence factor karilysin in human saliva.

Authors:  Peter Durand Skottrup; Rodrigo López; Miroslaw Ksiazek; Peter Højrup; Vibeke Baelum; Jan Potempa; Jakub Zbigniew Kaczmarek
Journal:  J Immunol Methods       Date:  2019-03-14       Impact factor: 2.303

Review 2.  Metabolic hormones in saliva: origins and functions.

Authors:  S Zolotukhin
Journal:  Oral Dis       Date:  2012-09-21       Impact factor: 3.511

3.  Salivary function impairment in type 2 Diabetes patients associated with concentration and genetic polymorphisms of chromogranin A.

Authors:  Evelyn Mikaela Kogawa; Daniela Corrêa Grisi; Denise Pinheiro Falcão; Ingrid Aquino Amorim; Taia Maria Berto Rezende; Izabel Cristina Rodrigues da Silva; Osmar Nascimento Silva; Octávio Luiz Franco; Rivadávio Fernandes Batista de Amorim
Journal:  Clin Oral Investig       Date:  2016-01-11       Impact factor: 3.573

Review 4.  Biological effects of obestatin.

Authors:  Jiang-Bo Li; Akihiro Asakawa; Kaichun Cheng; Yingxiao Li; Huhe Chaolu; Minglun Tsai; Akio Inui
Journal:  Endocrine       Date:  2011-03-20       Impact factor: 3.633

Review 5.  Ghrelin and Neurodegenerative Disorders-a Review.

Authors:  Limin Shi; Xixun Du; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

6.  Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents.

Authors:  Jeanelle Portelli; Leen Thielemans; Luc Ver Donck; Ellen Loyens; Jessica Coppens; Najat Aourz; Jeroen Aerssens; Katia Vermoesen; Ralph Clinckers; Anneleen Schallier; Yvette Michotte; Dieder Moechars; Graham L Collingridge; Zuner A Bortolotto; Ilse Smolders
Journal:  Neurotherapeutics       Date:  2012-07       Impact factor: 7.620

Review 7.  Preclinical evidence of ghrelin as a therapeutic target in epilepsy.

Authors:  Tongtong Ge; Wei Yang; Jie Fan; Bingjin Li
Journal:  Oncotarget       Date:  2017-06-02

8.  Biological function and clinical relevance of chromogranin A and derived peptides.

Authors:  Maria Angela D'amico; Barbara Ghinassi; Pascal Izzicupo; Lamberto Manzoli; A Di Baldassarre
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

9.  Adropin as a potential marker of enzyme-positive acute coronary syndrome.

Authors:  Suna Aydin; Mehmet Nesimi Eren; Musa Yilmaz; Mehmet Kalayci; Meltem Yardim; Omer Dogan Alatas; Tuncay Kuloglu; Huseyin Balaban; Tolga Cakmak; Mehmet Ali Kobalt; Ahmet Çelik; Suleyman Aydin
Journal:  Cardiovasc J Afr       Date:  2016-05-19       Impact factor: 1.167

Review 10.  Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy.

Authors:  An Buckinx; Dimitri De Bundel; Ron Kooijman; Ilse Smolders
Journal:  Biomedicines       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.